In small-animal oral solid dose operations, hydrocortisone acetate monohydrate is incorporated at 5 mg, 10 mg, and 20 mg label strengths per compressed tablet. Direct compression using spray-dried lactose monohydrate and microcrystalline cellulose (Avicel PH-102) exhibits content uniformity failure when the API particle size distribution exceeds D90 < 100 μm, because coarse corticosteroid crystals segregate in the feed frame of high-speed rotary presses. On a 10-station rotary tablet press fitted with 8 mm flat-faced bevel-edge tooling, controlled compression force between 8 kN and 12 kN produces tablet hardness in the range of 40–70 N per USP <1217> and friability below 0.8% per USP <1216>. Wet granulation becomes necessary when the formulation contains more than 30% of the API by weight or when the API exhibits static adhesion to stainless steel contact surfaces. The granulation endpoint is validated by loss on drying not exceeding 2.0% at 105°C, using a halogen moisture balance. Disintegrant croscarmellose sodium at 2–4% w/w and magnesium stearate at 0.5–1.0% w/w are added post-granulation in a V-blender for 10 minutes at 25 rpm. Dissolution is conducted in 900 mL of 0.5% sodium lauryl sulfate in pH 7.4 phosphate buffer per USP <711> Apparatus II at 50 rpm, with an acceptance criterion of not less than 75% released at 45 minutes. Batch-to-batch content uniformity RSD should remain below 2.0% per USP <905> for all three strengths. Compliant terminal products include scored tablets for weight-adjusted canine dosing at 0.5–1.0 mg/kg/day divided q12h, and feline tablets at 2.5–5 mg per cat q12h, packaged in PVC/aluminum blister cavities with desiccant canisters. Bioequivalence for multisource veterinary products follows VICH GL18, while veterinary medicinal product registration in the EU falls under Regulation (EU) 2019/6. Production-scale twin-shell blenders of 200 L working volume with intensifier bars at 1,500 rpm routinely achieve blend homogeneity below 3.0% RSD with 15-minute mixing cycles, whereas unvalidated extended blending beyond 25 minutes induces lubricant over-coating and retarded dissolution. Tablet press tooling is cleaned between API strengths using 70% isopropyl alcohol and air-knife residue removal to prevent cross-contamination carryover above the permitted 10 ppm threshold for corticosteroids under FDA 21 CFR Part 201 labeling requirements.

Why Does Hydrocortisone Sodium Succinate Require Step-Wise Lyophilization Instead of Snap Freezing for Equine and Bovine Injectable Presentations?

The sodium hemisuccinate ester is selected for aqueous injectable presentations because the free base and acetate forms are practically insoluble in water. Aseptic filling of 100 mg hydrocortisone equivalent per 5 mL Type I borosilicate glass vial is followed by lyophilization in a 10-shelf chamber with 1.2 m² shelf area per shelf. Snap freezing at -45°C without annealing produces an amorphous ice matrix that traps unfrozen solute pockets; when the shelf temperature is ramped directly to 25°C, the cake collapses because the product temperature exceeds the collapse temperature (Tc) of approximately -30°C for mannitol-cryoprotected hydrocortisone sodium succinate formulations. The validated cycle consists of thermal treatment at -45°C for 4 hours, followed by primary drying at -20°C shelf setpoint with chamber vacuum maintained between 80 mTorr and 120 mTorr for 8 hours, and secondary drying at 25°C for 8 hours until residual moisture by coulometric Karl Fischer titration is below 1.0% w/w. The collapse endpoint is detected by the pressure differential between a Pirani gauge and a capacitance manometer narrowing to within 10 mTorr. Reconstitution with 2.0 mL sterile water for injection must yield a clear solution within 60 seconds at 25°C; longer reconstitution times indicate sucrose-free glass-like cake structures caused by insufficient annealing. The phosphate buffer system formulated with monobasic and dibasic sodium phosphate at pH 7.0–8.0 restricts hydrolytic degradation of the succinate ester during the liquid hold period before freezing; holding bulk solution for more than 8 hours at 25°C before fill produces measurable hydrolytic cleavage and is documented in the batch record. Sterility assurance is anchored to USP <71> membrane filtration with R2A and TSB media, bacterial endotoxin testing to USP <85> with acceptance of not more than 0.5 EU/mg, and sub-visible particulate matter to USP <788> Light Obscuration Particle Count Test with NMT 6,000 particles ≥ 10 μm and NMT 600 particles ≥ 25 μm per container for the 5 mL presentation. The freeze-dried product is indicated for acute inflammatory conditions in equine laminitis, bovine septic shock, and canine Addisonian crisis; published stability data at 25°C/60% RH supports a 24-month shelf life when the elastomeric closure moisture ingress remains below 0.5 mg/vial/year.

Lyophilization Cycle Parameters for Hydrocortisone Sodium Succinate 100 mg/Vial

Parameter	Setpoint	Control Range
Shelf freezing temperature	-45°C	±2°C
Freeze hold time	4 hr	3–5 hr
Primary drying shelf temperature	-20°C	±2°C
Chamber vacuum	80 mTorr	80–120 mTorr
Primary drying duration	8 hr	6–10 hr
Secondary drying shelf temperature	25°C	±2°C
Secondary drying duration	8 hr	6–10 hr
Residual moisture by Karl Fischer	< 1.0% w/w	—

Ophthalmic Suspension pH Buffer Capacity and Preservative Partitioning in LDPE Dropper Systems

Aqueous hydrocortisone acetate suspensions intended for ocular administration in equine and companion animal species require simultaneous control of particle size distribution, buffer capacity, and preservative availability. Suspended API crystals with a laser diffraction D90 < 10 μm and D100 < 25 μm per ISO 13320:2020 minimize corneal abrasion and prevent drainage-duct obstruction; the particle size specification aligns with USP <771> ophthalmic product requirements. Sterile processing is executed by aseptic compounding rather than terminal steam sterilization because autoclaving at 121°C induces recrystallization of hydrocortisone acetate and shifts the particle size distribution beyond the 25 μm upper limit. Benzalkonium chloride at 0.01% w/v is the reference preservative, but cationic surfactant adsorption onto the negatively charged API particle surface reduces the free preservative concentration below the minimum inhibitory concentration for Pseudomonas aeruginosa; this partitioning is quantified by high-performance liquid chromatography after ultracentrifugation and requires adjustment to 0.012–0.015% benzalkonium chloride in some formulations. Preservative efficacy testing per USP <51> with Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Candida albicans, and Aspergillus brasiliensis is repeated on the final packaged LDPE dropper bottle because benzalkonium chloride partitions into low-density polyethylene sidewalls at 25°C/60% RH over 12 months. The buffer system uses 50 mM acetate at pH 6.8–7.2, deviating from the pH 5.0–5.5 range of maximum chemical stability for hydrocortisone acetate because tear film compatibility and corneal epithelial integrity require near-physiological pH. Isotonicity is adjusted to 280–320 mOsm/kg with sodium chloride, and viscosity is raised to 15–30 cP with hydroxypropyl methylcellulose 0.2–0.5% w/v to decrease settling velocity according to Stokes' law. Terminal presentations include 1% w/v hydrocortisone acetate ophthalmic suspension in 5 mL and 10 mL LDPE dropper bottles with tamper-evident overcap, intended for equine uveitis and canine keratoconjunctivitis sicca adjunctive therapy. Storage at 40°C/25% RH for 6 months per ICH Q1A(R2) is the stress condition for evaluating pH drift and particle aggregation; pH drift greater than 0.3 unit or D90 growth beyond 15 μm during the stress period triggers reformulation. Published data for continuous long-term physical stability of this specific suspension in LDPE packaging is limited, so real-time stability at 25°C/60% RH through 36 months is recommended.Within feed mill operations, hydrocortisone API intended for premix dilution is first milled to a particle size of D90 < 100 μm because low inclusion rates of 10–20 mg/kg complete feed demand extensive surface area for distributive mixing. Mixer testing on a 500 kg horizontal ribbon blender with 20-minute mixing time at 25 rpm must demonstrate a coefficient of variation not exceeding 5.0% across 10 sample points, per FDA CPG 7126.33 and FDA 21 CFR Part 558 medicated feed current good manufacturing practice expectations. Carryover into subsequent non-medicated feed batches is controlled to not more than 2% of the labeled hydrocortisone concentration by flushing the mixer, bucket elevator, and discharge screw conveyor with 10 kg ground corn for 5 minutes. Dust generation is suppressed by adding pharmaceutical-grade mineral oil at 0.5–1.0% w/w to the premix during the final 3 minutes of blending, which reduces airborne corticosteroid dust below the 0.1 mg/m³ occupational exposure limit band and protects mixer operators. Hydrocortisone premix for therapeutic medicated feed in neonatal calf scours adjunctive therapy is formulated at 10 mg/g carrier base using ground corn cobs or rice hulls as diluent; the premix is then diluted into complete calf starter feed at the feed mill at 10–20 mg hydrocortisone per kg complete feed. Corticosteroids are not approved as production enhancers in food-producing animals; any use in food-producing species falls under veterinary prescription and must comply with the withdrawal period specified by the national competent authority under FDA 21 CFR Part 530 or equivalent regional regulation. Terminal products include 1 kg and 25 kg multiwall paper bags with polyethylene liner, sealed against moisture ingress. Batch-to-batch variance in feed mill operations arises primarily from fluctuating ambient humidity above 60% RH, which causes API adhesion to mixer walls; preconditioning the mixer with a silica desiccant pack or installing a dehumidified air supply at 45% RH or lower stabilizes batch uniformity.

When Bulk Density Differential Exceeds 0.35 g/cm³ in Granule Carrier Selection for Top-Dress Administration

Before a granule top-dress formulation is finalized, the bulk density differential between the API powder and the carrier granule is measured per USP <616> Method I and Method II. A differential greater than 0.35 g/cm³ produces stratification during vibration and transport, with corticosteroid-rich fines migrating to the bottom of the container and causing supratherapeutic doses in the last portion administered. Hydrocortisone API typically exhibits a bulk density of 0.30–0.40 g/cm³; therefore lactose monohydrate or sucrose sphere carriers with bulk density above 0.75 g/cm³ require milling or blending with a lower-density cellulose-based diluent to reduce the differential to below 0.20 g/cm³. Wet granulation with polyvinylpyrrolidone K-30 at 5% w/w as binder solution is performed in a fluid bed granulator with top-spray configuration, inlet air temperature at 60°C, spray rate 20–30 g/min/kg of powder bed, and drying to loss on drying below 2.0% at 105°C. The dried granules are sized through a 20–60 mesh screen stack; the target Carr index remains below 18% and Hausner ratio below 1.20, indicating free-flowing characteristics suitable for volumetric dispensing into 1 kg high-density polyethylene pouches. Terminal granule presentations at 10 mg/g hydrocortisone are administered as a top dress on equine feed or small animal canned diets at 0.5–2.5 mg/kg body weight per day. Segregation testing per ASTM D6940/D6941 using a rotary splitter and sieve analysis of the 10 sampled fractions must show active content RSD below 5.0% after simulated 30-minute vibratory transport. Production-scale equipment includes Glatt GPCG 5 or equivalent fluid bed units with 5 kg working capacity and inlet air dew point below -20°C to prevent binder migration during spray application of the granulating fluid.

Compliance Checklist Matrix by Dosage Form

Dosage form	Primary compendial reference	Critical test designation
Compressed tablets	BP Veterinary Hydrocortisone Tablets	USP <905>, USP <711>
Lyophilized injection	USP Hydrocortisone Sodium Succinate for Injection	USP <71>, USP <85>, USP <788>
Ophthalmic suspension	USP Hydrocortisone Acetate Ophthalmic Suspension	USP <51>, USP <771>
Feed premix	FDA 21 CFR Part 558	Mixing uniformity CV ≤ 5.0%
Top-dress granules	BP Veterinary	USP <616>, USP <1174>
Compounded capsules	USP <795>	USP <905>
Oral drench solution	USP Hydrocortisone Sodium Phosphate Oral Solution	USP <791>, USP <1111>

Compounded Capsule-Fill Dilution Geometries for Weight-Banded Dosing in Feline and Canine Practice

Compounded veterinary capsules are prepared in 100 to 1,000 unit batches by licensed compounding pharmacies for individual patient prescriptions and weight-banded dispensing programs. Geometric dilution of hydrocortisone acetate with lactose monohydrate in 1:10 steps is mandatory when the target capsule strength is below 1 mg, because direct three-dimensional mixing of microgram-scale quantities with bulk diluent produces content uniformity RSD above 15%. The API is first milled to D90 < 75 μm and sieved through a 200-mesh screen to break agglomerates before the first dilution step. Hard gelatin or hydroxypropyl methylcellulose capsules of size #3 or #4 are filled on a semi-automatic 100-hole hand-operated filling plate; fill weight variation is controlled to not more than 5.0% per USP <905>. Dosing for canine inflammatory bowel disease is typically 0.4–1.0 mg/kg every 12 hours, while feline asthma protocols use 0.5–2.5 mg per cat every 12 hours; therefore weight-banded capsule strengths of 0.5 mg, 1 mg, and 2.5 mg are commercially practical. Quality control on each compounded batch involves assay by high-performance liquid chromatography with UV detection at 248 nm per USP <621> and absence of cross-contamination verified by swab testing at not more than 10 ppm residual hydrocortisone on shared equipment surfaces. The finished capsules are packaged in 60 mL amber high-density polyethylene vials with child-slip closures and desiccant sachets. Published long-term stability data for compounded hydrocortisone capsules is limited; beyond-use dates should not exceed 180 days per USP <795> unless the formulation and packaging are supported by a stability-indicating study.Routinely, oral drench solutions for neonatal ruminants and emergency small animal dosing are prepared as buffered aqueous systems containing the water-soluble hydrocortisone sodium phosphate ester at 5 mg/mL. The vehicle is 50 mM phosphate buffer at pH 6.8–7.4, which suppresses hydrolytic cleavage of the phosphate ester to the free base; a pH drift of more than 0.5 unit over 24 months at 25°C/60% RH is out of specification per ICH Q1A(R2). Preservatives methylparaben at 0.1% w/v and propylparaben at 0.02% w/v provide antimicrobial effectiveness per USP <51>; paraben solubility is maintained by adding sorbitol at 20% w/v as a co-solvent and palatability agent. The solution viscosity is adjusted to 15–30 cP with hydroxypropyl methylcellulose 0.2% w/v to reduce gastroesophageal reflux during drench administration in calves and foals. Manufacturing is conducted in a 2,000 L jacketed stainless steel mixing kettle with bottom-mounted homogenizer at 1,500 rpm and clarifying filtration through 0.45 μm polyethersulfone cartridge filters before filling into 100 mL and 500 mL amber high-density polyethylene bottles with graduated dosing cups. Microbial limits for non-sterile aqueous preparations are verified per USP <1111> with total aerobic microbial count not exceeding 10² CFU/mL and absence of Escherichia coli. Terminal doses for neonatal calf septicemia adjunctive therapy require 1–2 mg/kg hydrocortisone sodium phosphate intravenously or orally, whereas the oral drench concentration of 5 mg/mL permits accurate administration via calibrated dosing gun at 0.2–0.4 mL/kg. Batch-to-batch variability emerges when the paraben preservatives are added directly into cold buffer below 60°C, producing micellar haze and reduced preservative efficacy; the parabens are pre-dissolved in propylene glycol at 10% w/v before transfer into the main mixing vessel.